Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
IPO Year: n/a
Exchange: NASDAQ
Website: interpace.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2021 | Buy → Neutral | HC Wainwright & Co. |
●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year ●2021 Full Year Net Loss Improved $11.5 Million vs Prior Year ●Full year Cash Collections improved by 31% to $43.1 million and outpaced Revenue by nearly $2 million PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2021 and provided a business and financial update. "2021 has been a transformative year for Interpace," said Thomas Burnell, President and CEO. Burnell added, "The Company e
PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX:IDXG) ("Interpace") a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2022. Dr. Aggarwal replaces Eric B. Lev, both designees of Ampersand 2018 Limited Partnership, a Series B Preferred stockholder of the Company. Dr. Aggarwal has over thirty years of experience in both pharmaceutical services and clinical diagnostics. In addition to serving as Managing Partner of The Channel Group, Dr. Aggarwal provides strategic advisory services to companies with operations or investments in
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our Net Loss in the first quarter of 2022 was $2.2 million, which represents an improvement of approximately $2 million from the prior year first quarter, driven by higher Net Revenues and lower oper
●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly Improved Liquidity with Comerica Bank $7.5 Credit Facility ●Entered into $8 million term loan with BroadOak Fund, V, L.P. ●Announcing New Proposed $30 Million Rights Offering PARSIPPANY, NJ, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended September 30, 2021 and provided a business and financial update. "2021 has been a dynamic and meaningful year in the evolution of Interpace
●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company's Highest Revenue Quarter ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating Expense Containment ●Restructuring Exceeding Full-Year Savings Expectations ●On Track to Exceed Full Year 2021 Revenue Growth of 35% ●Q2 Cash Collections in Excess of $11 Million Representing Highest Collection Quarter PARSIPPANY, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended June 30, 2021 and provided a business and financial update. "Followin
● Q1 Revenue of $9.8 Million is Company's Highest as Combined Molecular Diagnostics and Pharma Services Business ● Q2 Revenue Expected to Exceed $11 million ● On Track to Exceed Full Year 2021 Revenue Growth of 35% ●Moving Up Target For EBITDA Breakeven from Q4 2021 to Q3 2021 PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update. "We are very pleased with our first quarter operating results which are on track and in accordance with our growth, restructuring and reprioritization p
Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior YearEstimates Fourth Quarter Net Revenue range of $9.0 million - $10.0 millionRealized Reimbursement on Higher ThyGeNEXT Pricing in JanuaryClosed $5 Million Bridge Loan Agreement with Existing Private Equity Investors and terminated the SVB credit facilityCash balance as of January 15, 2021 was $6.1 million net of restricted cash Conference Call and Webcast Thursday January 21, 2021 at 4:30 pm ET PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) today announced financial res
●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ●Initiates Full Year 2025 Revenue Guidance of approximately $38 million PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2025 and provided a business and financial update. First quarter Net Revenue was $11.5 million. Income from continuing operations in the first quarter
Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today announced that the Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) issued by the Medicare Administrative Contractor Novitas Solutions will go into effect, ending reimbursement for their PancraGEN® test. The Centers for Medicare & Medicaid Services (CMS) delayed implementation by 60 days earlier in the year and confirmed finalization of the LCD as of today, April 24, 2025. PancraGEN is a DNA-based diagnostic molecular test. It uniquel
●Q4 and FY Test volume increase 21% and 17% year-over-year ●Q4 and FY Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced preliminary financial and business results for the fiscal year and fourth quarter ended December 31, 2024. Fourth quarter Molecular Volume increased 21% year-over-year compared to Q4 2023, and 17% for the Full Year resulting in double-digit Q4 and YTD revenue growth. "The Company achieved record test volume, test revenue, income, and cash collections in Q4 and full year 2024," said Chris McCarthy, Chief Financial Office
PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today announced notification that the Centers for Medicare & Medicaid Services (CMS) directed its Medicare Administrative Contractors, Novitas and First Coast Service Options, Inc., to delay implementation of the Genetic Testing for Oncology Local Coverage Determination (LCD) (L39365), from February 23, 2025, to April 24, 2025. This change of effective date will allow the incoming Trump administration time to fully review the proposed policy changes, re-evaluate for themselves the supporting clinical evidence for the PancraGEN® assay
PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today responded to the final Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) issued by the Centers for Medicare & Medicaid Services (CMS). The new LCD establishes non-coverage for the Company's widely used PancraGEN® test. PancraGEN is a DNA-based diagnostic molecular test. It uniquely assesses the risk of pancreatic cyst progression to cancer by integrating the results of first-line tests and procedures with molecular test results. It has been offered since 2013 and provides insight to physicians to aid t
●Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ●Q3 Test volume up 26% year over year to record levels ●Q3 Cash collections of $11.3M; a $1.4M and 15% increase year-over-year ●Q3 Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the third quarter ended September 30, 2024 and provided a business and financial update. Third quarter Net Revenue was $12.3 million. Operating costs per test for the third quarter were approximately 11% lower than the same period of 2023. Income from continuing op
PARSIPPANY, NJ, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced that its Series B Preferred Stock investors, Ampersand Capital Partners and 1315 Capital (the "Investors"), have exchanged (the "Exchange") their existing Series B Preferred Stock for a new issuance of Series C Preferred Stock in order to assist the Company in seeking an uplisting of its Common Stock to Nasdaq. The Investors exchanged an aggregate of 47,000 shares of the Company's existing Series B Preferred Stock comprising 28,000 shares of Series B Preferred Stock held by Ampersand Capital Partners and 19,000 shares of Series B Preferred Stock held by
●Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ●Q2 Test volume up 12% year-over-year to record levels ●Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ●Q2 Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the second quarter ended June 30, 2024 and provided a business and financial update. Second quarter Net Revenue was $12.0 million. Operating expenses for the second quarter were approximately 14% lower than the same period of 2023. Income from continuing operations in the sec
PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today responded to the undefined extension granted by Centers for Medicare & Medicaid Services (CMS) to Novitas, its Medicare Administrative Contractor (MAC). Novitas announced late last week that CMS granted an extension to the final decision for Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) in order for all comments received in response to the proposed changes to be thoroughly considered. LCD (L39365) includes PancraGEN®, a DNA-based diagnostic molecular test. It uniquely assesses the risk of pancreat
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences® (OTCQX:IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-abstract as part of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract e16359 (asco.org/abstracts) highlights the evolving landscape of sequencing technologies for analyzing short tandem repeats (STRs) in pancreatic cancer detection. STRs, alternatively known as microsatellites, function as regulators of gene expression. STRs are prone to hypermutation with alterations correlated to pathogenici
10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
10-K/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
10-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
3 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
3 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
HC Wainwright & Co. downgraded Interpace Biosciences from Buy to Neutral
HC Wainwright & Co. reiterated coverage of Interpace Biosciences with a rating of Buy and set a new price target of $9.00 from $6.00 previously
HC Wainwright resumed coverage of Interpace Biosciences with a rating of Buy and set a new price target of $6.00 from $10.00 previously
SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13G/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13G/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13G - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)
SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)